

# CITATION REPORT

List of articles citing

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

DOI: 10.1016/s2468-1253(16)30024-3

The Lancet Gastroenterology and Hepatology, 2016, 1, 185-19

**Source:** <https://exaly.com/paper-pdf/64270954/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
288	Tenofovir alafenamide for hepatitis B: evolution or revolution?. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 174-175	18.8	2
287	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 196-206	18.8	259
286	Treatment of chronic hepatitis B infection-2017. <i>Liver International</i> , <b>2017</b> , 37 Suppl 1, 59-66	7.9	19
285	Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). <i>Liver International</i> , <b>2017</b> , 37 Suppl 1, 45-51	7.9	37
284	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 370-398	13.4	2354
283	Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. <b>2017</b> , 31, 299-309		41
282	Tenofovir Alafenamide: A Review in Chronic Hepatitis B. <b>2017</b> , 77, 1017-1028		26
281	Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 707-716	3.8	21
280	Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. <b>2017</b> , 11, 999-1008		16
279	Bone and the Immune System. <b>2017</b> , 45, 911-924		81
278	Management of Chronic Hepatitis B in Pregnancy. <b>2017</b> , 51, 789-795		10
277	Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. <b>2017</b> , 11, 1095-1104		15
276	Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 900-909	18.8	129
275	Drugs in Development for Hepatitis B. <b>2017</b> , 77, 1263-1280		21
274	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. <b>2017</b> , 23, 935-940		56
273	Hepatitis B and D. <b>2017</b> , 584-627		
272	Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. <b>2017</b> , 216, S792-S796		14

271	Unmet Needs in Clinical and Basic Hepatitis B Virus Research. <b>2017</b> , 216, S750-S756		16
270	Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. <b>2017</b> , 11, 3197-3204		19
269	Renal safety of tenofovir and/or entecavir in patients with chronic HBV mono-infection. <b>2017</b> , 13, 1273-1285		9
268	Updated Hepatitis B Guidance: Implications for liver transplant patients. <b>2018</b> , 24, 465-469		11
267	An expert consensus for the management of chronic hepatitis B in Asian Americans. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1181-1200	6.1	24
266	Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B. <b>2018</b> , 25, 1139-1150		1
265	Current and future directions of management of hepatitis B: steps toward a cure. <b>2018</b> , 13, 189-209		1
264	GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. <b>2018</b> , 151, 39.e1-39.e17		4
263	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <b>2018</b> , 67, 1560-1599		1460
262	Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?. <b>2018</b> , 16, 153-161		11
261	Long-term safety and efficacy of nucleos(t)ide analogue therapy in hepatitis B. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 84-89	7.9	23
260	Towards HBV curative therapies. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 102-114	7.9	44
259	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 730-737	6.1	42
258	Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. <b>2018</b> , 27, 102-112		10
257	siRNA drug development against hepatitis B virus infection. <b>2018</b> , 18, 609-617		19
256	Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1673-1681	6.1	14
255	Chronic Hepatitis B Infection: A Review. <b>2018</b> , 319, 1802-1813		266
254	AuthorsReply. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 224-225	18.8	1

253	Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. <b>2018</b> , 24, 1483-1489		12
252	Management of chronic hepatitis B before and after liver transplantation. <b>2018</b> , 9, 79-84		6
251	Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses. <b>2018</b> , 147, 378-399		28
250	Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	15
249	Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. <b>2018</b> , 153, 2-11		27
248	Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. <b>2018</b> , 1, 156-217		26
247	Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. <i>Journal of Virus Eradication</i> , <b>2018</b> , 4, 72-79	2.8	62
246	Management of hepatitis B and C infections in rheumatologic disease. <b>2018</b> , 32, 848-868		2
245	Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. <b>2018</b> , 17, 502-510		1
244	Management of chronic hepatitis B during pregnancy. <b>2018</b> , 6, 257-262		11
243	Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection. <b>2018</b> ,		24
242	Improvements in the management of chronic hepatitis B virus infection. <b>2018</b> , 12, 1153-1166		6
241	Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1282-1289	6.1	13
240	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 793-802	13.4	45
239	Hepatitis B: Standard and Novel Treatment Options. <b>2018</b> , 12, 19-23		3
238	Current and prospective therapies for acute liver failure. <b>2018</b> , 64, 493-522		8
237	[Chronic hepatitis B and D (delta) : Current and future treatments]. <i>Der Internist</i> , <b>2018</b> , 59, 519-527	o	
236	Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. <b>2018</b> , 11, 561-573		28

235	Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs. <b>2018</b> , 70, 684-711		23
234	Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <b>2018</b> , 5, e357-e365		65
233	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. <b>2018</b> , 320, 379-396		390
232	Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. <b>2018</b> , 11, 1756284818786108		15
231	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. <b>2018</b> , 62,		27
230	Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection. <b>2018</b> , 38, 1051-1057		13
229	Future Drugs in the Treatment of HBV. <b>2018</b> , 105-117		
228	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 984-992	6.1	37
227	Hepatitis B. <b>2018</b> , 395-420		
226	GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. <b>2018</b> , 151, 39.e1-39.e17		1
225	Anti-hepatitis B virus effects of the traditional Chinese herb <i>Artemisia capillaris</i> and its active enynes. <b>2018</b> , 224, 283-289		16
224	Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan. <b>2019</b> , 54, 182-193		20
223	Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <b>2019</b> , 18, 363-369		
222	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 93-159	6.9	87
221	Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients. <b>2019</b> , 220, 1469-1476		3
220	Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. <b>2019</b> , 8, 207		17
219	Antiviral Consideration for Transplantation Including Drug Resistance. <b>2019</b> , 953-975		1
218	Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF- $\beta$ /Smad3 signaling pathway. <b>2019</b> , 20, 163		2

217	Liver Disease in Human Immunodeficiency Virus Infection. <b>2019</b> , 23, 309-329		2
216	WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. <b>2019</b> , 23, 417-432		17
215	Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?. <b>2019</b> , 33, 681-692		3
214	Phosphonate prodrugs: an overview and recent advances. <b>2019</b> , 11, 1625-1643		24
213	Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B. <b>2019</b> , 33, e13740		5
212	Nonliver Comorbidities in Patients With Chronic Hepatitis B. <b>2019</b> , 14, 126-130		2
211	Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection. <b>2019</b> , 18, 322-330		1
210	A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals. <b>2019</b> , 16,		13
209	Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. <i>Liver International</i> , <b>2019</b> , 39, 1868-1875	7.9	51
208	Drugs in the Pipeline for HBV. <b>2019</b> , 23, 535-555		39
207	A case of entecavir-induced Fanconi syndrome. <b>2019</b> , 8, 256-260		4
206	Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. <b>2019</b> , 91, 1804-1810		21
205	Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide. <b>2019</b> , 20 Suppl 7, 1-16		8
204	Updates on Chronic HBV: Current Challenges and Future Goals. <b>2019</b> , 17, 271-291		34
203	Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. <b>2019</b> , 34, 2004-2010		29
202	Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. <b>2019</b> , 20, 873-885		6
201	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 35-44	13.4	20
200	British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. <b>2019</b> , 20 Suppl 3, s2-s85		12

199	[Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach]. <b>2019</b> , 40, 590-598		0
198	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. <b>2019</b> , 17, 1850-1859.e4		26
197	Reactivation of hepatitis B virus infection in patients with hematologic disorders. <b>2019</b> , 104, 435-443		20
196	Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. <b>2019</b> , 91, 1295-1300		7
195	Abstracts. <i>Liver International</i> , <b>2019</b> , 39, 2420-2468	7.9	
194	Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. <b>2019</b> , 69, 1983-1994		77
193	Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. <b>2019</b> , 26, 561-567		32
192	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , <b>2019</b> , 118, 7-38	3.2	25
191	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. <b>2019</b> , 114, 746-757		16
190	Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. <b>2019</b> , 34, 501-506		3
189	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <b>2020</b> , 71, 444-455		19
188	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <b>2020</b> , 158, 215-225.e6		94
187	Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. <b>2020</b> , 18, 747-749		10
186	Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. <b>2020</b> , 38, 181-192		4
185	Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients. <b>2020</b> , 50, 402-404		2
184	Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. <b>2020</b> , 4, 429-432		9
183	Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. <b>2020</b> , 115, 406-414		7
182	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 847-854	13.4	26

181	Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection. <b>2020</b> , 174, 104693		7
180	Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. <b>2020</b> , 92, 329-338		15
179	Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B. <b>2020</b> , 54, 633-641		10
178	Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphtropism in Antiviral Treatment and Oncogenesis. <i>Microorganisms</i> , <b>2020</b> , 8,	4.9	2
177	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <b>2020</b> , 396, 239-254		94
176	An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. <b>2020</b> , 55, 811-823		19
175	Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. <b>2021</b> , 23, e13522		3
174	Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. <b>2020</b> , 10, 13021		5
173	Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. <i>PLoS ONE</i> , <b>2020</b> , 15, e0237586 <sup>3.7</sup>		0
172	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <b>2020</b> , 43, 559-587		6
171	Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1377-1386	6.1	9
170	Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?. <b>2020</b> , 55, 1023-1036		4
169	A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. <b>2020</b> , 9, 1051-1065		1
168	Waking Up the Sleeping Giant: Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy. <b>2020</b> , 16, 198-203		0
167	HBV replication inhibitors. <b>2020</b> , 179, 104815		17
166	Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. <b>2020</b> , 55, 496-514		14
165	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 500-512	6.1	3
164	An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer. <b>2020</b> , 593, 113611		3



163	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 406-417	18.8	22
162	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 441-453	18.8	45
161	7-Deaza-7-fluoro modification confers on 4Rcyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. <b>2020</b> , 176, 104744		6
160	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 420-421	18.8	
159	Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. <b>2020</b> , 43, 169-177		1
158	Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. <b>2020</b> , 50, 892-923		27
157	Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients. <b>2020</b> , 27, 818-825		2
156	Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 169-177	0.1	
155	Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1169-1179	6.1	19
154	Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. <i>Liver International</i> , <b>2020</b> , 40, 1578-1589	7.9	21
153	A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. <b>2020</b> , 19, 2325958220919231		21
152	Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: A network meta-analysis. <b>2021</b> , 28, 40-50		3
151	Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. <b>2021</b> , 28, 51-60		1
150	Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. <b>2021</b> , 15, 427-435		6
149	Sequential therapy from entecavir to tenofovir alafenamide continuous entecavir monotherapy for patients with chronic hepatitis B. <b>2021</b> , 5, 34-40		3
148	Pharmacotherapy options for managing hepatitis B in children. <b>2021</b> , 22, 449-467		0
147	Increasing Age and Nonliver Comorbidities in Patients with Chronic Hepatitis B in Taiwan: A Nationwide Population-Based Analysis. <b>2021</b> , 39, 266-274		3
146	Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance. <b>2021</b> , 28, 30-39		4

145	Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. <i>Liver International</i> , <b>2021</b> , 41, 1254-1264	7.9	8
144	The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study. <b>2021</b> , 28, 592-600		2
143	SASLT practice guidelines for the management of Hepatitis B virus - An update. <b>2021</b> , 27, 115-126		1
142	Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. <b>2021</b> , 73, e3324-e3332		9
141	The Impact of Tenofovir Disoproxil Fumarate on Reduced Bone Mineral Density and Fractures in Liver Transplant Recipients. <b>2021</b> , 53, 215-220		
140	Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma. <b>2021</b> , 60, 417-421		4
139	Combination of Entecavir or Tenofovir with Pegylated Interferon- $\alpha$ For Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
138	First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 123	3	3
137	Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B. <b>2021</b> , 11,		3
136	Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq. <b>2021</b> , 185, 114485		5
135	Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis. <b>2021</b> , 9, 335-344		0
134	Position statement on the use of Tenofovir Alafenamide for the treatment of chronic Hepatitis B Virus infection in Africa. <b>2020</b> , 11, 57-63		
133	Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
132	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 346-359	6.9	3
131	3-year Treatment of Tenofovir Alafenamide . Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China. <b>2021</b> , 9, 324-334		1
130	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. <b>2021</b> , 86, 473-481		2
129	Spontaneous reactivation of hepatitis B virus with a frameshift mutation in the precore region in an elderly hepatitis B virus carrier with lifestyle-related diseases. <b>2021</b> , 14, 1202-1210		0
128	Blinding in Clinical Trials for Chronic Liver Diseases. <b>2021</b> , 41, 163-171		0

127	Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251552	3.7	1
126	Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. <b>2021</b> ,		4
125	Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. <b>2021</b> , 1		1
124	What Should Be Done to Re-evaluate Cessation of Nucleos(t)ide Analog Therapy for Chronic Hepatitis B Infection?. <b>2021</b> , 1, 93-102		
123	A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. <b>2021</b> , 14, 139-156		1
122	Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. <b>2021</b> , 21, 567		3
121	Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg seroconversion. <b>2021</b> , 28, 1160-1168		
120	Bioequivalence Evaluation of Two Formulations of Tenofovir Alafenamide Tablets in Healthy Subjects Under Fasting and Fed Conditions. <b>2021</b> , 15, 2551-2562		0
119	Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. <i>Liver International</i> , <b>2021</b> , 41 Suppl 1, 9-14	7.9	1
118	Real-life data of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in the patients with chronic hepatitis B: a single-center experience. <b>2021</b> , 3, 239-245		
117	S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion (AWMF-Register-Nr. 021-11). <b>2021</b> , 59, 691-776		9
116	Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. <b>2021</b> ,		3
115	Current management & future directions in post-liver transplant recurrence of viral hepatitis. <b>2021</b> , 3, 100027		0
114	Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 701061	4.9	2
113	Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. <b>2021</b> , 22, 2427-2433		1
112	Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. <b>2021</b> , 27, 5088-5099		1
111	Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. <b>2021</b> , 5, 1085-1091		2
110	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , <b>2021</b> , 15, 1083-1092	8.8	5

109	Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B. <b>2021</b> , 22, 1325		
108	Combination Treatment with the Vimentin-Targeting Antibody hzV5F and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks. <b>2021</b> , 10,		2
107	Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. <b>2021</b> , 28, 1570-1578		2
106	Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1134-1149	6.1	1
105	Guidelines for Prevention and Treatment of Chronic Hepatitis B. <b>2021</b> , 9, 769-791		5
104	Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial. <b>2021</b> ,		1
103	Challenges in the discontinuation of chronic hepatitis B antiviral agents. <b>2021</b> , 13, 1042-1057		1
102	Asociaci3n Mexicana de Hepatolog3a A.C. Clinical guideline on hepatitis B. <b>2021</b> , 86, 403-432		
101	Should Treatment Indications for Chronic Hepatitis B Be Expanded?. <b>2021</b> , 19, 2006-2014		7
100	Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs. <b>2021</b> , 56, 1008-1021		0
99	Asociaci3n Mexicana de Hepatolog3a A.C. Clinical guideline on hepatitis B. <b>2021</b> , 86, 403-403		
98	Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. <b>2021</b> , 37, 262-267		2
97	Hepatitis B and Hepatitis D Infections in the Transplant Setting. <b>2021</b> , 927-950		
96	Nucleos(t)ide Therapy and Long-Term Outcomes. <b>2021</b> , 287-318		
95	Novel Therapy for Functional Cure of Chronic Hepatitis B Virus Infection. <b>2021</b> , 455-473		
94	Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. <b>2021</b> , 8, 2049936120985954		5
93	Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients. <b>2021</b> , 5, 258-263		3
92	Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. <b>2020</b> ,		4

91	Stopping nucleos(t)ide analog treatment in chronic hepatitis B [Who and when?. <b>2017</b> , 1, 135-139		1
90	Hepatitis B reactivation: diagnosis and management. <b>2020</b> , 14, 565-578		9
89	Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide. <b>2017</b> , 12, 324-333		21
88	Early renal injury indicators can help evaluate renal injury in patients with chronic hepatitis B with long-term nucleos(t)ide therapy. <i>World Journal of Clinical Cases</i> , <b>2020</b> , 8, 6306-6314	1.6	2
87	Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?. <i>Clinical and Molecular Hepatology</i> , <b>2017</b> , 23, 125-127	6.9	2
86	Unmet need in chronic hepatitis B management. <i>Clinical and Molecular Hepatology</i> , <b>2019</b> , 25, 172-180	6.9	32
85	Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
84	Updated Treatment of Chronic Hepatitis B. <i>Korean Journal of Medicine</i> , <b>2019</b> , 94, 252-262	0.5	1
83	Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection. <i>Journal of Inflammation Research</i> , <b>2021</b> , 14, 5489-5500	4.8	1
82	HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 713981	4.9	5
81	Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide. <i>Journal of the Formosan Medical Association</i> , <b>2021</b> ,	3.2	0
80	Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	6
79	Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2021</b> , 14, 1315-1329	2.1	0
78	Chronic Hepatitis B. <b>2022</b> , 203-253		
77	Change in renal tubular function and phosphorus metabolism by switching from previous nucleotide analogues to Tenofovir alafenamide fumarate in treatment of chronic hepatitis B. <i>Acta Hepatologica Japonica</i> , <b>2018</b> , 59, 252-255	0.3	
76	Tenofovir Alafenamide: A New Drug With Various Ambiguous Aspects in Treatment of Chronic Hepatitis B Infection. <i>Archives of Clinical Infectious Diseases</i> , <b>2019</b> , In Press,	3.1	
75	Regenerative Therapy for Liver Cirrhosis. <b>2019</b> , 203-215		
74	Hepatitis B and Hepatitis D Infections in the Transplant Setting. <b>2020</b> , 1-24		

73	Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 32, 208-213	2.2	
72	Recomendaciones en el tratamiento actual de la infección crónica por el virus de la hepatitis B. <i>Hepatología</i> , <b>2020</b> , 36-54	0.1	
71	Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 73-79	2.2	2
70	Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. <i>Liver International</i> , <b>2021</b> ,	7.9	3
69	Clinical Characteristics of Hepatitis B Virus Patients After Switching to Tenofovir Alafenamide Fumarate: A Retrospective Observational Study. <i>Cureus</i> , <b>2020</b> , 12, e10380	1.2	1
68	Chapter XX Antiviral Treatment and Cancer Control. <i>Recent Results in Cancer Research</i> , <b>2021</b> , 217, 325-354		
67	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 559-587	0.1	0
66	Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. <i>Journal of Virus Eradication</i> , <b>2018</b> , 4, 72-79	2.8	36
65	Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alafenamide for chronic hepatitis B. <i>Biomedical Reports</i> , <b>2021</b> , 14, 12	1.8	2
64	Review of Current and Potential Treatments for Chronic Hepatitis B Virus Infection. <i>Gastroenterology and Hepatology</i> , <b>2021</b> , 17, 367-376	0.7	1
63	Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide.. <i>Biomedical Reports</i> , <b>2022</b> , 16, 6	1.8	
62	Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study. <i>PeerJ</i> , <b>2021</b> , 9, e12527	3.1	0
61	Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
60	Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study. <b>2021</b> , 9, e003195		0
59	Clinical management of chronic hepatitis B: A concise overview. <i>United European Gastroenterology Journal</i> , <b>2021</b> ,	5.3	2
58	Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , <b>2021</b> , 78, 284-288	0.6	
57	Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alafenamide for chronic hepatitis B. <i>Biomedical Reports</i> , <b>2020</b> , 14, 1-1	1.8	1
56	Comparison of Tenofovir Alafenamide and Entecavir Therapy in Patients with Chronic Hepatitis B Initially Treated with Tenofovir Disoproxil: A Retrospective Observational Survey. <i>Hepatitis Monthly</i> , <b>2022</b> , 21,	1.8	2

55	Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.. <i>Hepatology International</i> , <b>2022</b> , 16, 282	8.8	0
54	Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 796901	4.9	0
53	Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.. <i>Applied Health Economics and Health Policy</i> , <b>2022</b> , 1	3.4	1
52	Current Trend in Antiviral Therapy for Chronic Hepatitis B.. <i>Viruses</i> , <b>2022</b> , 14,	6.2	3
51	Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0262764	3.7	0
50	Review: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	1
49	The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264075	3.7	
48	Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? AuthorsR reply.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> , 55, 1044-1045	6.1	
47	Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine.. <i>Viruses</i> , <b>2022</b> , 14,	6.2	0
46	[Treatment of parenterally transmittable viral hepatitis].. <i>Der Internist</i> , <b>2022</b> , 63, 388	0	
45	Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> , 55, 1042-1043	6.1	0
44	KASL clinical practice guidelines for management of chronic hepatitis B.. <i>Clinical and Molecular Hepatology</i> , <b>2022</b> , 28, 276-331	6.9	2
43	Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis.. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> ,	6.9	0
42	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.. <i>Liver International</i> , <b>2022</b> ,	7.9	0
41	Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study.. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 489	3	
40	Rheumatologie und Hepatologie interdisziplinär <i>Aktuelle Rheumatologie</i> , <b>2021</b> , 46, 552-560	0.1	
39	Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	1
38	First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.. <i>Hepatology Communications</i> , <b>2022</b> ,	6	1

37	Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data.. <i>Clinical and Experimental Hepatology</i> , <b>2022</b> , 8, 7-13	2.2	
36	Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	2
35	Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study. <i>Antiviral Therapy</i> , <b>2022</b> , 27, 135965352210823	1.6	0
34	First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects. <i>Frontiers in Pharmacology</i> , 13,	5.6	
33	HERACLIS-TAF : a multicentre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. <i>Alimentary Pharmacology and Therapeutics</i> ,	6.1	0
32	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	2
31	One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B. <i>Medicine (United States)</i> , <b>2022</b> , 101, e29269	1.8	
30	Pharmacological approaches to prevent vertical transmission of HIV and HBV. <i>Expert Review of Clinical Pharmacology</i> ,	3.8	
29	Post-liver transplant HBV infection (Review). <b>2022</b> , 24, 31-38		
28	Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. Volume 14, 87-100		1
27	Recent Drug Development in the Woodchuck Model of Chronic Hepatitis B. <b>2022</b> , 14, 1711		0
26	Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.		
25	Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B. <b>2022</b> , 56, 916-917		0
24	MicroRNA targeted therapy in hepatitis. <b>2022</b> , 549-561		0
23	Anti-HBV Drugs in Liver Cirrhosis. <b>2022</b> , 1-10		0
22	Risk of HCC in Patients with HBV, Role of Antiviral Treatment.		0
21	Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients. Volume 16, 3263-3274		0
20	Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study. <b>2022</b> , 101, e30630		0



19	Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. <b>2022</b> , 23, 11335	0
18	Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir. <b>2022</b> ,	0
17	Safety, pharmacokinetics, and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: a randomized, placebo-controlled Phase 1 study.	1
16	Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study. 1-8	0
15	Sequence characterization of extracellular HBV RNA in patient plasma.	0
14	Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease. <b>2022</b> , 85, 331-337	0
13	Health inequalities in the management of chronic Hepatitis B Virus infection in patients from sub-Saharan Africa in high income countries. <b>2022</b> , 100623	1
12	Fibrosis-4 index efficiently predicts chronic hepatitis and liver cirrhosis development based on a large-scale data of general population in Japan. <b>2022</b> , 12,	0
11	Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort Study.	0
10	Modern principles of etiotropic therapy for chronic hepatitis B and C. <b>2023</b> , 26, 7-15	0
9	The Use of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide for Preventing Vertical Transmission of Hepatitis B. <b>2023</b> , 57, 127-138	0
8	Comparison of the side effects of antivirals in chronic hepatitis B patients: a single-center experience. <b>2022</b> , 85, 587-592	0
7	Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario.	0
6	HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide. <b>2023</b> ,	0
5	Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21. 13,	0
4	Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma.	0
3	Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers. <b>2023</b> , 18, 401-416	0
2	Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients.	0

- 1 Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.

o